Kazue Mizuno

Dr. Kazue Mizuno

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YMYu Rebecca Miao
Yu Rebecca Miao
KTKaushik Thakkar
Kaushik Thakkar
CCCan Cenik
Can Cenik
DJDadi Jiang
Dadi Jiang
KMKazue Mizuno
Kazue Mizuno
AGAmato J. Giaccia
Amato J. Giaccia
Disease relapse and treatment-induced immunotoxicity pose significant clinical challenges for patients with hematological cancers. Here, we reveal distinctive requirements for neutralizing TNF receptor ligands APRIL and BAFF and their receptor activity in MM and DLBCL, impacting protein translation and production in MM cells and modulating the translation efficiency of the ATM interactor (ATMIN/ACSIZ). Therapeutically, we investigated the use of BCMA decoy receptor (sBCMA-Fc) as an inhibitor of APRIL and BAFF. While wild-type sBCMA-Fc effectively blocked APRIL signaling in MM, it lacked activity in DLBCL due to its weak BAFF binding. To expand the therapeutic utility of sBCMA-Fc, we engineered an affinity-enhanced mutant sBCMA-Fc fusion molecule (sBCMA-Fc V3) 4- and 500-fold stronger in binding to APRIL and BAFF, respectively. The mutant sBCMA-Fc V3 clone significantly enhanced antitumor activity against both MM and DLBCL. Importantly, we also demonstrated an adequate toxicity profile and on-target mechanism of action in nonhuman primate studies.

4 April 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
KFKyohei Fukuda
Kyohei Fukuda
HBHiroaki Baba
Hiroaki Baba
MYMie Yoshida
Mie Yoshida
KKKouichi Kitabayashi
Kouichi Kitabayashi
SKShinjirou Katsushima
Shinjirou Katsushima
AMAkira Mizuno
Akira Mizuno
The assessment of airborne viruses in air is a critical step in the design of appropriate prevention and control measures. Hence, herein, we developed a novel wet-type electrostatic air sampler using a viral dissolution buffer containing a radical scavenging agent, and verified the concentration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in the air of hospital rooms inhabiting coronavirus disease 2019 (COVID-19) patients and public areas. RNA damage caused by corona discharge was negligible when Buffer AVL was used as the collecting electrode. The viral RNA concentration in the air of the room varied by patient: 3.9 × 103 copy/m3 on the 10th day after onset in a mild case and 1.3 × 103 copy/m3 on the 18th day in a severe case. Viral RNA levels were 7.8 × 102 and 1.9 × 102 copy/m3 in the air of the office and food court, respectively, where people removed their masks when eating and talking, but it remained undetected in the station corridor where all the people were wearing masks. The assessment of airborne SARS-CoV-2 RNA using the proposed sampler can serve as a basis for the safe discontinuation of COVID-19 isolation precautions to identify exposure hotspots and alert individuals at increased infection risks.

1 September 2012 in Journal of Microbiological Methods
Verified
Journal Article
Closed access
SMSatoshi Mitarai
Satoshi Mitarai
RKRyouji Karinaga
Ryouji Karinaga
Hiroyuki YamadaHiroyuki Yamada
Hiroyuki Yamada
KMKazue Mizuno
Kazue Mizuno
KCKinuyo Chikamatsu
Kinuyo Chikamatsu
THTomoyuki Hatano
Tomoyuki Hatano

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
HBHiroaki Baba
Hiroaki Baba
KFKyohei Fukuda
Kyohei Fukuda
MYMie Yoshida
Mie Yoshida
KKKouichi Kitabayashi
Kouichi Kitabayashi
SKShinjirou Katsushima
Shinjirou Katsushima
AMAkira Mizuno
Akira Mizuno
Monitoring of airborne viruses in the air is a crucial step in the design of appropriate prevention and control measures. We used a novel wet-type electrostatic precipitator air sampler using a viral dissolution buffer containing a radical scavenging agent to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in the air of a hospital room of coronavirus disease-2019 (COVID-19) patients and public areas. The concentration of SARS-CoV-2 RNA in the air of hospital rooms of a total of 10 consented patients hospitalized for COVID-19 was measured using an electrostatic precipitator air sampler between February and August 2022. The air sampler was also used to measure the concentration of SARS-CoV-2 RNA in the air of an office room during the working hour, a food court of a shopping mall during lunchtime on a holiday, and a station corridor during morning and evening commuting hours. The office room and food court were 340 m3 and 2000 m3, respectively, and contained about 30 and 300 people, respectively, who removed their masks when eating, drinking, and talking. The station corridor was 1500 m3 in size and contained 100 people all wearing masks and had been walking during sampling. SARS-CoV-2 RNA collected in Buffer AVL was extracted using QIAamp Viral RNA mini kit and quantified by the real-time quantitative PCR (RT-qPCR) targeting the N2 region. SARS-CoV-2 RNA concentration in the air of each space was calculated from the amount of collected viral RNA, the air volume required for the collection, and the particle collection efficiency of the sampler. Clinical characteristics of the patients and SARS-CoV-2 viral RNA concentrations in the hospital room air. RT-qPCR detection results of SARS-CoV-2 in the indoor environment and suspended concentrations. The electrostatic precipitator air sampler is useful for measuring SARS-CoV-2 RNA in the air of hospital rooms of COVID-19 patients and of public spaces. Airborne viral RNA monitoring may aid in appropriate airborne infection control. Hiroaki Baba, MD, PhD, Amano Co., Ltd.: Grant/Research Support Kyohei Fukuda, n/a, AMANO Co., Ltd.: KF was supported by AMANO Co., Ltd. in the form of salaries. Mie Yoshida, n/a, AMANO Co., Ltd.: MY was supported by AMANO Co., Ltd. in the form of salaries. Kouichi Kitabayashi, n/a, AMANO Co., Ltd.: KK was supported by AMANO Co., Ltd. in the form of salaries. Shinjirou Katsushima, n/a, AMANO Co., Ltd.: SK was supported by AMANO Co., Ltd. in the form of salaries. Hajime Kanamori, MD, PhD, MPH, Amano Co., Ltd.: Grant/Research Support Koichi Tokuda, MD, PhD, MPH, AMANO Co., Ltd.: Grant/Research Support